Alizyme is fighting the good fight against ills brought on by the good life. The development-stage biotechnology company licenses drug candidates and develops them. It targets conditions prevalent primarily in industrialized countries, including obesity, type 2 diabetes (often associated with obesity), and ulcerative colitis. Alizyme is focused on developing a family of lipase inhibitors, which prevent the body from absorbing fat. In addition to its pipeline of treatments for lifestyle-related conditions, the company is developing a drug for mucositis, cancer therapy-induced damage to the gastrointestinal tract.

Entelos using its PhysioLab technology, the company develops computer models of diseases that drug makers and other researchers can use to design drugs and other therapies more effectively. The disease models integrate known genomic and proteomic data with physiologic, environmental, and other information collected from clinical trials, case studies, and other sources. Entelos has developed PhysioLab models for asthma, diabetes, obesity, and rheumatoid arthritis. The models are built in partnership with such firms as Eli Lilly, PDL Biopharma, and UCB Pharma.

deCODE genetics, Inc. (deCODE) is a bio-pharmaceutical company developing and marketing products for the treatment, diagnosis, and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in therapeutic areas, and applies its discoveries in human genetics to bring to market deoxyribonucleic acid (DNA)-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. In November 2009, the Company announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware.

Roche NimbleGen, founded in 1999, serves clients such as academic institutions, government laboratories, and pharmaceutical companies. It is a part of Roche Diagnostics. Roche NimbleGen displays agility in testing DNA. Formerly NimbleGen Systems, the company develops products and services for the analysis of genomes, which include the complete genetic material of an organism. The company produces high-density arrays of long oligo probes offering the deep high quality information necessary to study genomic variation base on ist proprietary Maskless Array Sythesis technology. By understanding the nature and function of genomes, scientists are able to improve a variety of medical and agricultural products.

Kreatech Biotechnology company develops tools used by pharmaceutical companies and medical researchers to detect and label RNA, DNA, and proteins. Its labeling kits, DNA probes, and other products are used in applications such as drug development and the diagnosis of disease. The company's investors include 3i Group, Alafi Capital, and Life Sciences Partners. Kreatech has formed alliances with many pharmaceutical and instrumentation firms, including heavyweights such as GE Healthcare Bio-Sciences and PerkinElmer.

Symbollon is a specialty pharmaceutical company focused on the development and commercialization of proprietary drugs based on its I2 technology. I2 is the chemical symbol for molecular iodine. Molecular iodine is the active species of iodine, a proven fast acting, broad-spectrum antimicrobial and therapeutic. Formed in 1986, Symbollon completed its initial public offering in December 1993. Since that time we have pursued product applications for our technology in two distinct areas; women’s healthcare and antimicrobial applications.In female health, Symbollon has developed a proprietary oral tablet based on our technology that generates I2 in situ (the stomach of the patient). We refer to this drug as IoGen. In 2000, Symbollon completed Phase I and II clinical trials evaluating IoGen as a potential treatment for fibrocystic breast disease. Phase III pivotal trials will be conducted in 2005. We believe that IoGen may also be useful for the treatment and prevention of other types of excess cell growth in female reproductive tissue, such as endometriosis, ovarian cysts and pre-menopausal breast cancer.

IRIX Pharmaceuticals develops, tests, and manufactures drugs and drug ingredients for pharmaceutical companies. Services include discovery support, process research and development, clinical supply, manufacturing, and commercial production. It also helps clients work through the regulatory red tape. The company maintains three facilities in South Carolina. Its Florence facility has laboratories devoted to developing and testing new candidates. IRIX was formed in 1996 by CEO Guy Steenrod, former president of Roche Carolina -- the process discovery and development arm of Roche Pharmaceutical -- and a group of South Carolina investors.

GeneFluidics, Inc. develops electrochemical sensor platform for molecular analysis. Its solutions perform bioassays with sensitivity to picogram/ml concentrations for immunoassays and femtomolar concentrations for genetic assays. The company’s products include sensor chip arrays; Proteus, a modular robotic system; and Asklepios, the multi-channel microfluidics cartidge system. Its products are used for human diagnostics, animal health, environmental monitoring, and blood banking applications. The company was incorporated in 2000 and is headquartered in Monterey Park, California.

Ranbaxy Pharmaceuticals Inc. company, the US arm of Indian generic pharmaceuticals giant Ranbaxy Laboratories Limited, makes and markets about 50 generic and over-the-counter (OTC) drugs. It accounts for about a quarter of its parent's annual revenues. RPI's generic offerings, produced by manufacturing subsidiary Ohm Laboratories, include anti-infectives and treatments for cardiovascular, gastrointestinal, and central nervous system disorders. Its OTC products include analgesics, antihistamines, and decongestants. Sister subsidiary Ranbaxy Laboratories, Inc. (RLI) develops branded pharmaceuticals.

Kendle International Inc. was founded in 1981 and is based in Cincinnati, Ohio. Kendle International Inc. is a global clinical research organization (CRO) that provides a range of Phase I-IV global clinical development services to the biopharmaceutical industry. The Company augments the research and development activities of biopharmaceutical companies by offering clinical research services and information technology designed to reduce drug development time and expense. Kendle International Inc. is managed in two reportable segments: Early Stage and Late Stage. The Early Stage business focuses on the Company’s Phase I operations while Late Stage is comprised of clinical development services related to Phase II through III clinical trials conducted worldwide, late phase clinical development services related to Phase IIIB and IV clinical trials conducted worldwide, regulatory affairs and biometrics offerings. In June 2008, the Company announced the acquisition of DecisionLine Clinical Research Corporation.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.